SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.
20549
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of
1934
March 05, 2020
Commission
File Number 001-14978
SMITH & NEPHEW
plc
(Registrant's
name)
Building 5, Croxley Park,
Hatters Lane, Watford, Hertfordshire, WD18 8YE,
England
(Address
of registrant's principal executive offices)
[Indicate
by check mark whether the registrant files or will file
annual
reports
under cover Form 20-F or Form 40-F.]
Form
20-F
X
Form 40-F
---
---
[Indicate
by check mark if the registrant is submitting the Form 6-K
in
paper
as permitted by Regulation S-T Rule 101(b)(1).]
Yes
No X
---
---
[Indicate
by check mark if the registrant is submitting the Form 6-K
in
paper
as permitted by Regulation S-T Rule 101(b)(7).]
Yes
No X
---
---
[Indicate
by check mark whether by furnishing the information
contained
in this
Form, the registrant is also thereby furnishing information to
the
Commission
pursuant to Rule 12g3-2 (b) under the Securities Exchange Act
of
1934.]
Yes
No X
---
---
If
"Yes" is marked, indicate below the file number assigned to
the
registrant
in connection with Rule 12g3-2 (b) : 82- n/a.
Smith+Nephew announces departure of
Chief Financial
Officer
5 March 2020
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology
business, announces that Graham Baker will step down from the Board
and his position as Chief Financial Officer ('CFO') on 30 April
2020 in order to take up a new CFO role outside the healthcare
sector.
Smith+Nephew is at an advanced stage of appointing Graham's
successor and expects to announce the Company's new CFO in the near
future. Ian Melling, Senior Vice President Group Finance, will
serve as interim CFO and join the Executive Committee but not the
Board during this period.
Roland Diggelmann, Chief Executive Officer, Smith+Nephew,
commented:
"Graham has been a highly valued member of our team and has been
instrumental in many of the changes that are supporting our recent
improved performance. He leaves with our very best wishes for the
future.
"We are confident that we will be able to announce Graham's
replacement shortly and that this will be a proven CFO with
excellent global listed-company and healthcare
experience."
Graham Baker, Chief Financial Officer, commented:
"I am immensely proud of what Smith+Nephew, and the Finance and IT
teams in particular, have achieved over the last three years and I
appreciate very much the opportunity I have had to work with
Roland, both as Board Member and CEO. While I regret not being able
to continue the great work we have started, my new opportunity was
too compelling personally and professionally to miss."
No further disclosure obligations arise under paragraphs (1) to (6)
of LR 9.6.13 R of the UK Listing Authority's Listing Rules in
respect of these appointments.
This announcement includes inside information as defined in Article
7 of the Market Abuse Regulation No. 596/2014.
The person responsible for arranging the release of this
announcement on behalf of Smith+Nephew is Susan Swabey, Company
Secretary.
Remuneration
In connection with his departure from the Company on 30 April 2020,
Graham will be paid in accordance with the Company's Remuneration
Policy and the terms of his service agreement. He will continue to
receive his salary, benefits and pension contributions in the
normal way up to 30 April 2020 and all unvested awards under the
Performance Share Programme and the Equity Incentive Programme will
lapse on his leaving the Company.
Enquiries
Investors
Andrew
Swift +44
(0) 1923 477433
Smith+Nephew
Media
Charles Reynolds
+44
(0) 1923 477314
Smith+Nephew
Susan Gilchrist / Charis
Gresser
+44 (0) 207404 5959
Brunswick
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business that exists
to restore people's bodies and their self-belief by using
technology to take the limits off living. We call this purpose
'Life Unlimited'. Our 17,500+ employees deliver this mission every
day, making a difference to patients' lives through the
excellence of our product portfolio, and the invention and
application of new technologies across our three global
franchises of Orthopaedics, Advanced Wound Management and Sports
Medicine & ENT. Founded in Hull, UK, in 1856, we now operate in
more than 100 countries, and generated annual sales of $5.1 billion
in 2019. Smith+Nephew is a constituent of the FTSE100 (LSE:SN,
NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used to refer
to Smith & Nephew plc and its consolidated subsidiaries,
unless the context requires otherwise.
For more information about Smith+Nephew, please
visit www.smith-nephew.com and
follow us on Twitter, LinkedIn, Instagram or Facebook.
Forward-looking Statements
This document may contain forward-looking statements that may or
may not prove accurate. For example, statements regarding expected
revenue growth and trading margins, market trends and our product
pipeline are forward-looking statements. Phrases such as "aim",
"plan", "intend", "anticipate", "well-placed", "believe",
"estimate", "expect", "target", "consider" and similar expressions
are generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith+Nephew, these factors include: economic
and financial conditions in the markets we serve, especially those
affecting health care providers, payers and customers; price levels
for established and innovative medical devices; developments in
medical technology; regulatory approvals, reimbursement decisions
or other government actions; product defects or recalls or other
problems with quality management systems or failure to comply with
related regulations; litigation relating to patent or other claims;
legal compliance risks and related investigative, remedial or
enforcement actions; disruption to our supply chain or operations
or those of our suppliers; competition for qualified personnel;
strategic actions, including acquisitions and dispositions, our
success in performing due diligence, valuing and integrating
acquired businesses; disruption that may result from transactions
or other changes we make in our business plans or organisation to
adapt to market developments; and numerous other matters that
affect us or our markets, including those of a political, economic,
business, competitive or reputational nature. Please refer to the
documents that Smith+Nephew has filed with the U.S. Securities and
Exchange Commission under the U.S. Securities Exchange Act of 1934,
as amended, including Smith+Nephew's most recent annual report on
Form 20-F, for a discussion of certain of these factors. Any
forward-looking statement is based on information available to
Smith+Nephew as of the date of the statement. All written or oral
forward-looking statements attributable to Smith+Nephew are
qualified by this caution. Smith+Nephew does not undertake any
obligation to update or revise any forward-looking statement to
reflect any change in circumstances or in Smith+Nephew's
expectations.
◊ Trademark of Smith+Nephew. Certain marks registered US
Patent and Trademark Office.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
Smith
& Nephew Plc
(Registrant)
Date: March
05, 2020
By: /s/
Susan Swabey
-----------------
Susan
Swabey
Company
Secretary